DMC Group LLC Has $394,000 Position in DexCom, Inc. (NASDAQ:DXCM)

DMC Group LLC increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 34.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,882 shares of the medical device company’s stock after purchasing an additional 1,492 shares during the quarter. DMC Group LLC’s holdings in DexCom were worth $394,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Canada Pension Plan Investment Board boosted its position in DexCom by 189.1% during the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock worth $75,471,000 after buying an additional 435,401 shares during the period. Massachusetts Financial Services Co. MA raised its stake in shares of DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after acquiring an additional 353,019 shares during the last quarter. Bellevue Group AG lifted its holdings in shares of DexCom by 33.5% during the first quarter. Bellevue Group AG now owns 1,221,197 shares of the medical device company’s stock worth $169,380,000 after purchasing an additional 306,604 shares during the period. Magnetar Financial LLC bought a new stake in shares of DexCom in the second quarter worth $31,793,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of DexCom by 41.3% in the second quarter. Dimensional Fund Advisors LP now owns 919,650 shares of the medical device company’s stock worth $104,282,000 after purchasing an additional 268,802 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

DXCM stock opened at $72.38 on Friday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. The business has a 50-day simple moving average of $69.97 and a two-hundred day simple moving average of $100.22. The company has a market capitalization of $28.78 billion, a P/E ratio of 46.70, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same period last year, the business earned $0.34 EPS. The business’s revenue was up 15.3% on a year-over-year basis. Research analysts expect that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Stifel Nicolaus lifted their target price on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, October 12th. Oppenheimer decreased their target price on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, July 26th. Wells Fargo & Company lowered their price target on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a report on Friday, July 26th. Finally, Robert W. Baird upped their price objective on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Seven equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $110.73.

Insider Buying and Selling

In other DexCom news, EVP Sadie Stern sold 426 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other DexCom news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,824 shares of company stock worth $126,390. 0.30% of the stock is owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.